中华传染病杂志
中華傳染病雜誌
중화전염병잡지
CHINESE JOURNAL OF INFECTIOUS DISEASES
2014年
7期
21-25
,共5页
康婧%刘静%张子宁%郭晓临%丁海波%罗晓光%尚红
康婧%劉靜%張子寧%郭曉臨%丁海波%囉曉光%尚紅
강청%류정%장자저%곽효림%정해파%라효광%상홍
蒙特利尔认知评估量表%人类免疫缺陷病毒%神经认知功能%高效抗反转录病毒治疗
矇特利爾認知評估量錶%人類免疫缺陷病毒%神經認知功能%高效抗反轉錄病毒治療
몽특리이인지평고량표%인류면역결함병독%신경인지공능%고효항반전록병독치료
Montreal cognitive assessment%Human immunodeficiency virus%Neurocognitive function%Highly active antiretroviral therapy
目的:探索 HIV 感染者神经认知功能特点,比较不同认知功能患者 HAART 的效果。方法采用中文版蒙特利尔认知评估量表(MoCA)对118例 HIV 感染者和62例 HIV 阴性对照者进行认知功能评估;对进行 HAART 的59例 HIV 感染者入选时及随访1年后检测 CD4+ T 淋巴细胞和血清病毒载量。计量资料比较采用 t 检验,计数资料比较采用χ2检验或 Fisher 确切概率法检验,单因素和多因素分析采用双变量 Logistic 回归分析。结果 HIV 感染组神经认知功能损害的发生率为46.6%(55/118),明显高于对照组的12.9%(8/62),差异有统计学意义(χ2=20.30, P<0.05);HIV 感染组在视空间能力、画钟测验、命名、注意力、抽象、延迟记忆等方面得分明显劣于对照组(t 值分别为-3.761、-2.638、-4.263、-3.769、-3.858和-3.111,均 P <0.05)。 HAART 患者中,MoCA <26分组与MoCA 正常组3个时间点(治疗前、治疗后入选时及随访1年)的病毒载量差异均无统计学意义(t 值分别为0.557、0.737和-0.758,均 P>0.05);两组治疗前 CD4+ T 淋巴细胞数为(135±77)/μL 比(155±80)/μL ,HAART 时间为(22.29±21.2)个月比(18.74±16.63)个月,均差异无统计学意义(t 值分别为-0.968和0.702,均 P>0.05),前者入选时 CD4+ T 淋巴细胞数为(286±127)/μL ,随访1年后 CD4+ T淋巴细胞数为(334±122)/μL ,均显著低于后者的(363±160)/μL 和(411±152)/μL (t 值分别为-2.027和 -2.067,均 P <0.05)。多因素分析显示,年龄(OR =1.044,95% CI :1.008~1.081,P <0.05)和接受教育时间(OR =0.820,95% CI :0.723~0.930,P<0.05)是 HIV 感染者认知功能损害的独立预测因子。结论 HIV感染者神经认知功能受损常见,表现为多领域功能障碍,且治疗后患者免疫功能的恢复较差。 MoCA 可作为 HIV 感染者认知功能的临床筛查量表,认知功能与治疗前后病毒载量水平无明显关系。
目的:探索 HIV 感染者神經認知功能特點,比較不同認知功能患者 HAART 的效果。方法採用中文版矇特利爾認知評估量錶(MoCA)對118例 HIV 感染者和62例 HIV 陰性對照者進行認知功能評估;對進行 HAART 的59例 HIV 感染者入選時及隨訪1年後檢測 CD4+ T 淋巴細胞和血清病毒載量。計量資料比較採用 t 檢驗,計數資料比較採用χ2檢驗或 Fisher 確切概率法檢驗,單因素和多因素分析採用雙變量 Logistic 迴歸分析。結果 HIV 感染組神經認知功能損害的髮生率為46.6%(55/118),明顯高于對照組的12.9%(8/62),差異有統計學意義(χ2=20.30, P<0.05);HIV 感染組在視空間能力、畫鐘測驗、命名、註意力、抽象、延遲記憶等方麵得分明顯劣于對照組(t 值分彆為-3.761、-2.638、-4.263、-3.769、-3.858和-3.111,均 P <0.05)。 HAART 患者中,MoCA <26分組與MoCA 正常組3箇時間點(治療前、治療後入選時及隨訪1年)的病毒載量差異均無統計學意義(t 值分彆為0.557、0.737和-0.758,均 P>0.05);兩組治療前 CD4+ T 淋巴細胞數為(135±77)/μL 比(155±80)/μL ,HAART 時間為(22.29±21.2)箇月比(18.74±16.63)箇月,均差異無統計學意義(t 值分彆為-0.968和0.702,均 P>0.05),前者入選時 CD4+ T 淋巴細胞數為(286±127)/μL ,隨訪1年後 CD4+ T淋巴細胞數為(334±122)/μL ,均顯著低于後者的(363±160)/μL 和(411±152)/μL (t 值分彆為-2.027和 -2.067,均 P <0.05)。多因素分析顯示,年齡(OR =1.044,95% CI :1.008~1.081,P <0.05)和接受教育時間(OR =0.820,95% CI :0.723~0.930,P<0.05)是 HIV 感染者認知功能損害的獨立預測因子。結論 HIV感染者神經認知功能受損常見,錶現為多領域功能障礙,且治療後患者免疫功能的恢複較差。 MoCA 可作為 HIV 感染者認知功能的臨床篩查量錶,認知功能與治療前後病毒載量水平無明顯關繫。
목적:탐색 HIV 감염자신경인지공능특점,비교불동인지공능환자 HAART 적효과。방법채용중문판몽특리이인지평고량표(MoCA)대118례 HIV 감염자화62례 HIV 음성대조자진행인지공능평고;대진행 HAART 적59례 HIV 감염자입선시급수방1년후검측 CD4+ T 림파세포화혈청병독재량。계량자료비교채용 t 검험,계수자료비교채용χ2검험혹 Fisher 학절개솔법검험,단인소화다인소분석채용쌍변량 Logistic 회귀분석。결과 HIV 감염조신경인지공능손해적발생솔위46.6%(55/118),명현고우대조조적12.9%(8/62),차이유통계학의의(χ2=20.30, P<0.05);HIV 감염조재시공간능력、화종측험、명명、주의력、추상、연지기억등방면득분명현렬우대조조(t 치분별위-3.761、-2.638、-4.263、-3.769、-3.858화-3.111,균 P <0.05)。 HAART 환자중,MoCA <26분조여MoCA 정상조3개시간점(치료전、치료후입선시급수방1년)적병독재량차이균무통계학의의(t 치분별위0.557、0.737화-0.758,균 P>0.05);량조치료전 CD4+ T 림파세포수위(135±77)/μL 비(155±80)/μL ,HAART 시간위(22.29±21.2)개월비(18.74±16.63)개월,균차이무통계학의의(t 치분별위-0.968화0.702,균 P>0.05),전자입선시 CD4+ T 림파세포수위(286±127)/μL ,수방1년후 CD4+ T림파세포수위(334±122)/μL ,균현저저우후자적(363±160)/μL 화(411±152)/μL (t 치분별위-2.027화 -2.067,균 P <0.05)。다인소분석현시,년령(OR =1.044,95% CI :1.008~1.081,P <0.05)화접수교육시간(OR =0.820,95% CI :0.723~0.930,P<0.05)시 HIV 감염자인지공능손해적독립예측인자。결론 HIV감염자신경인지공능수손상견,표현위다영역공능장애,차치료후환자면역공능적회복교차。 MoCA 가작위 HIV 감염자인지공능적림상사사량표,인지공능여치료전후병독재량수평무명현관계。
Objective To explore neurocognitive characteristics of human immunodeficiency virus (HIV)-infected patients ,and to compare the efficacy of highly active antiretroviral therapy (HAART ) among patients with different cognitive functions .Methods Cognitive function was evaluated using the Montreal cognitive assessment (MoCA) Chinese version in 118 HIV-positive patients and 62 HIV-negative controls .Among 59 patients on HAART ,CD4 + T cell count and viral load were assessed at enrollment and one-year follow-up .The mean of measurement data was compared using t test ,and enumeration data was analyzed using chi-squared or Fisher exact test when appropriate .Univariate and multivariate analysis were examined using bivariate Logistic regression models .Results Compared with control group ,HIV-infected group was characterized by higher rate of neurocognitive impairment (46 .6% vs 12 .9% , t =20 .30 ,P< 0 .05) ,and generally lower MoCA subscores for visuospatial abilities ,the clock drawing test , naming ,attention ,abstraction and delayed recall (t= - 3 .761 , - 2 .638 , - 4 .263 , - 3 .769 , - 3 .858 and- 3 .111 ,respectively ,all P< 0 .05) .Among patients on HAART ,subjects who scored < 26 showed no significant differences in viral load at three time points (pre-HAART ,post-HAART at enrollment and one-year follow-up) with those who scored ≥ 26 (t = 0 .557 ,0 .737 and - 0 .758 ,respectively ,all P >0 .05) .The former group had lower CD4 + T cell counts both at enrollment ([286 ± 127]/μL vs [363 ± 160]/μL) and one-year follow-up ([334 ± 122]/μL vs [411 ± 152]/μL) than the latter group (t= - 2 .027 and - 2 .067 ,respectively ,both P < 0 .05 ) ,while there were no obvious differences of pretreatment CD4 + T cell counts ([135 ± 77]/μL vs [155 ± 80]/μL) and HAART duration ([22 .29 ± 21 .20] months vs [18 .74 ± 16 .63] months) between these two groups (t= - 0 .968 and 0 .702 ,respectively ,both P>0 .05) .Multivariate analysis revealed that age (OR = 1 .044 ,95% CI :1 .008 - 1 .081 , P < 0 .05) and education time (OR = 0 .820 ,95% CI :0 .723 - 0 .930 , P < 0 .05 ) were independent predictors for neurocognitive impairment among HIV-infected patients . Conclusions Neurocognitive impairment is common among HIV-infected patients ,which is characterized by poor performance in multiple domains , and patients with neurocognitive impairment performed poorly in immune recovery .MoCA could be a useful screening tool of cognitive function in HIV-infected patients . Neurocognitive function has no relationship with pre- and post-treatment viral levels .